[New diagnostic tests for rheumatoid arthritis]

Area of Science:

• Immunology
• Biochemistry
• Rheumatology

Context:

• Rheumatoid arthritis (RA) diagnosis relies on several biomarkers, including rheumatoid factor (RF), anti-agalactosyl IgG antibody (CARF), and anti-cyclic citrullinated peptide antibody (anti-CCP).
• Existing biomarkers show variable sensitivity and specificity for RA detection.
• Matrix metalloproteinase-3 (MMP-3) correlates with RA disease activity and prognosis.

Purpose:

• To evaluate the diagnostic performance of individual biomarkers (RF, CARF, anti-CCP, MMP-3) for rheumatoid arthritis (RA).
• To assess the efficacy of novel combination assays (MMP-3 or CARF, MMP-3 or anti-CCP) in diagnosing RA and early RA.
• To compare the diagnostic superiority of anti-CCP and combination assays against traditional markers.

Summary:

• Anti-cyclic citrullinated peptide antibody (anti-CCP) demonstrated higher sensitivity (76.0%) and specificity (91.5%) compared to rheumatoid factor (RF) and anti-agalactosyl IgG antibody (CARF).
• Matrix metalloproteinase-3 (MMP-3) showed potential for evaluating RA activity and predicting joint destruction.
• Combination assays of "MMP-3 or CARF" and "MMP-3 or anti-CCP" achieved the highest sensitivities (86.7% for RA, 91.7% and 83.3% for early RA, respectively).

Impact:

• Combination assays significantly improve the sensitivity for diagnosing both established and early rheumatoid arthritis.
• These findings suggest that "MMP-3 or CARF" and "MMP-3 or anti-CCP" assays are valuable tools for clinical diagnosis of RA.
• The study highlights the potential of combining biomarkers to enhance diagnostic accuracy in rheumatology.